An announcement from Neurogene (NGNE) is now available.
Neurogene Inc. has reported promising safety and tolerability outcomes from its Phase 1/2 gene therapy trial for Rett syndrome, highlighting that its treatment, NGN-401, shows no serious adverse events or toxicity in patients. This update, revealed at a major gene and cell therapy conference, is a positive sign for investors and stakeholders looking for advancements in gene therapy treatments.
For a thorough assessment of NGNE stock, go to TipRanks’ Stock Analysis page.
